A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer
Phase of Trial: Phase III
Latest Information Update: 01 Jul 2019
At a glance
- Drugs Selumetinib (Primary) ; Iodine radioactive
- Indications Thyroid cancer
- Focus Registrational; Therapeutic Use
- Acronyms ASTRA
- Sponsors AstraZeneca
- 28 Jun 2019 This trial has been completed in Denmark, according to European Clinical Trials Database.
- 18 Apr 2019 The trial has been completed in Sweden - MPA.
- 03 Apr 2019 The trial has been completed in France.